Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP982525.RAX40q532fsd_fMECrFs0oe3cTOo5DCBLMUd-X46Vxw7w130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP982525.RAX40q532fsd_fMECrFs0oe3cTOo5DCBLMUd-X46Vxw7w130_assertion type Assertion NP982525.RAX40q532fsd_fMECrFs0oe3cTOo5DCBLMUd-X46Vxw7w130_head.
- NP982525.RAX40q532fsd_fMECrFs0oe3cTOo5DCBLMUd-X46Vxw7w130_assertion description "[The majority of patients with neuroblastoma are assigned to the high-risk group based on age at diagnosis, stage, histology, MYCN status, and DNA ploidy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP982525.RAX40q532fsd_fMECrFs0oe3cTOo5DCBLMUd-X46Vxw7w130_provenance.
- NP982525.RAX40q532fsd_fMECrFs0oe3cTOo5DCBLMUd-X46Vxw7w130_assertion evidence source_evidence_literature NP982525.RAX40q532fsd_fMECrFs0oe3cTOo5DCBLMUd-X46Vxw7w130_provenance.
- NP982525.RAX40q532fsd_fMECrFs0oe3cTOo5DCBLMUd-X46Vxw7w130_assertion SIO_000772 22588779 NP982525.RAX40q532fsd_fMECrFs0oe3cTOo5DCBLMUd-X46Vxw7w130_provenance.
- NP982525.RAX40q532fsd_fMECrFs0oe3cTOo5DCBLMUd-X46Vxw7w130_assertion wasDerivedFrom befree-2016 NP982525.RAX40q532fsd_fMECrFs0oe3cTOo5DCBLMUd-X46Vxw7w130_provenance.
- NP982525.RAX40q532fsd_fMECrFs0oe3cTOo5DCBLMUd-X46Vxw7w130_assertion wasGeneratedBy ECO_0000203 NP982525.RAX40q532fsd_fMECrFs0oe3cTOo5DCBLMUd-X46Vxw7w130_provenance.